Nutritional Advice El Mondo
Objectives:
The benefit of IVIG (Intravenous Immunoglobulin) therapy for COVID-19 remains controversial. Therefore, this review article has been conducted.
Does intravenous immunoglobulin therapy reduce mortality in patients with COVID-19?
Study design:
This review article included 4 RCTs and 3 retrospective cohort studies with a total of 825 hospitalized patients.
Overall, the quality of the 7 included studies was low.
Results and conclusions:
The investigators found the severity of COVID-19 is significantly associated with the efficiency of intravenous immunoglobulin therapy.
The investigators found, in critical subgroup, intravenous immunoglobulin therapy significantly reduced the mortality of COVID-19 infection with 43%, compared with the control group [RR = 0.57, 95% CI = 0.42 to 0.79, I2 = 0%].
There was no significant difference in the severe [RR = 0.76, 95% CI = 0.51 to 1.14, I2 = 35%] or non-severe subgroups [RR = 1.39, 95% CI = 0.23 to 8.23, I2 = 20%].
The investigators concluded intravenous immunoglobulin therapy has demonstrated clinical efficacy on critical ill patients with COVID-19. There may be a relationship between the efficacy of intravenous immunoglobulin therapy and the COVID-19 disease severity. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from intravenous immunoglobulin therapy are warranted in the future.
Original title:
Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis by Xiang HR, Cheng X, [...], Peng X.
Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084608/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.